Regulatory approval of anti-cancer drugs occurs typically after demonstration of clinical benefit in registration trials. Over the last 15 years, new drug development has focused on numerous mechanisms of action including conventional cytotoxic agents, inhibition of oncogenic signaling pathways, angiogenesis and immune modulation. In recent years, there has been substantial enthusiasm for immunotherapy agents [1–4]. However, the differential efficacy, safety, tolerability and price of these agents relative to other anti-neoplastic drugs are uncertain.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oW8f1A
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2Gchesc via IFTTT
-
Abstract Determining the cause of unexplained death in all age groups, including infants, is a priority in forensic medicine. The triple r...
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2BeOBVJ via IFTTT
-
This paper presents an adaptive multiuser transceiver scheme for DS-CDMA systems in which pilot symbols are added to users’ data to estimate...
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2rxuJIO via IFTTT
-
Abstract In this paper we present the study of a skull belonging to a young male from the Italian Bronze Age showing three perimortem inju...
-
Find out more about the wide range of A Levels and full time courses available at Longley Park Sixth Form College, the only independent Sixt...
-
Abstract To measure integral doses in image-guided radiation therapy, we developed an integral condenser dosimeter comprising a disposable...
-
Objectives. To assess the association between short-term postoperative cognitive dysfuction (POCD) and inflammtory response in patients unde...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου